Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs CRON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: TLPH 1 – 5 CRON Matrix Metrics: TLPH 2 – 8 CRON

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas CRON carries 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin).

  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs CRON
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.26
-3.48% 1D
Market Cap $1.2B
TTM Revenue $206M
Forward P/E 13.3x
Beta / 30D Vol 0.35β · 40% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 46.0 Fund 51.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.9 · SMA20: $3.41 · SMA50: $3.32

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 5 CRON)

Columns: Metric · TLPH · CRON
1. Valuation Multiples TLPH
Forward P/E 1.0x 13.3x
Trailing P/E 1.0x 21.3x
PEG Ratio N/M N/M
EV / Revenue N/M 4.1x
2. Growth & Scale CRON
Revenue Growth (YoY) +0.0% +74.6%
Earnings Growth (YoY) +0.0% -44.7%
TTM Revenue (USD) $1,000 $206M
Market Cap $53.7M $1.2B
3. Profitability & Quality CRON
Gross Margin N/A 46.3%
Operating Margin -1474700.0% 6.1%
Net Profit Margin 0.0% 28.0%
Return on Equity (ROE) -143.4% 6.1%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) -$15M EBITDA $65M
Cash Flow Margin N/A 31.6%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $410M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 118.4% (100th %ile) 45.9% (20th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CRON
OpEx & R&D Intensity N/A 40.2% of Rev ($83M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (2) vs CRON (8)
Institutional Metric TLPH CRON Criterion Row Edge
Market Capitalization
Scale
$53.7M $1.2B Larger Scale CRON
Trailing P/E Ratio
Valuation
1.0x 21.3x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 13.3x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +74.6% Higher Growth CRON
Operating Margin (TTM)
Profitability
-1474700.0% 6.1% Higher Margin CRON
Net Profit Margin
Profitability
0.0% 28.0% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
-143.4% 6.1% Higher ROE CRON
52-Week Range Position
Momentum
20% ($1–$2) 60% ($2–$4) Stronger Trend CRON
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 0.35β · 40% Vol Lower Realized Risk CRON
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 53.9 / 100 (HOLD) Higher Composite CRON
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $206M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) $65M ($410M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +21.92 pp
TLPH: -20.29% · CRON: +1.63%
3M Horizon CRON +30.48 pp
TLPH: -28.85% · CRON: +1.63%
6M Horizon CRON +16.54 pp
TLPH: +7.98% · CRON: +24.52%
1Y Horizon CRON +49.56 pp
TLPH: -18.01% · CRON: +31.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs CRON. Trailing 12-month operating profitability (TLPH -1474700.0% vs CRON 6.1%) and valuation multiples (TLPH 1.0x vs CRON 13.3x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
CRON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$206M
Gross Margin46.3%
Op. Margin6.1%
ROE / Fwd P/E6.1% · 13.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRON CONSOLIDATION
57d in phase · OBV NEUTRAL
Current IV 45.9%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs CRON Key Questions & Quantitative Answers

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas CRON carries 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRON leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with CRON at +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $206M for CRON. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 40.2% of Rev ($83M) (0 disclosures) for CRON.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CRON trades at 13.3x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (31.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus CRON (6.1% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, CRON carries 45.9% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.